Symptomatic or prophylactic treatment of weekend migraine: an open-label, nonrandomized, comparison study of frovatriptan versus naproxen sodium versus no therapy

Figures & data

Table 1 Demographic and migraine history characteristics of the 28 patients at baseline

	n = 28
Age (years, means ± SD)	36 ± 12
Females (n, %)	18 (64)
Duration of migraine (years, means ± SD)	8 ± 6
Number of monthly migraine attacks in the previous	5 ± 1
3 months (means ± SD)
Use of triptans in the previous 3 months (n, %)	9 (32)
Patients with moderate or severe attacks (n, %)	12 (43)

Note: Data are shown as mean (± SD), or absolute (n) and relative frequency (%).

Abbreviation: SD, Standard deviation.

Figure 1 Average score (and 95% confidence interval) of migraine severity in all subjects and in those not taking rescue medication.

Notes: Data are shown for frovatriptan (open bars), naproxen sodium (dashed bars), and no therapy periods (full bars). P values of between-treatment differences are reported: *P < 0.05 frovatriptan versus naproxen sodium; **P < 0.001 frovatriptan versus no therapy; ***P < 0.001 frovatriptan versus naproxen sodium or versus no therapy; ^##P < 0.001 naproxen sodium versus no therapy.

Figure 2 Average score (and 95% confidence interval) of migraine severity in subjects not taking rescue medication, according to weekend day.

Notes: Data are shown for frovatriptan (open bars), naproxen sodium (dashed bars), and no therapy periods (full bars). P values of between-treatment differences are reported: *P , 0.05 frovatriptan versus naproxen sodium; **P , 0.001 frovatriptan versus naproxen sodium; ***P , 0.001 frovatriptan versus no therapy.

Figure 3 Frequency (%) of episodes treated with rescue medication during treatment with frovatriptan (open bar), naproxen sodium (dashed bar) or during no therapy (full bar).

Note: Corresponding odds ratio (OR), 95% confidence intervals and P values of frovatriptan versus comparators are reported on top of each bar.